IL17A and lung carcinoma: GSEA results demonstrated marked upregulation of the “interleukin-17 signaling pathway.” Notably, the interleukin-17 (IL-17) signaling pathway has been previously established to contribute to the progression of lung cancer bone metastasis (Zhou et al., 2023).